{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T15:53:22Z","timestamp":1782489202059,"version":"3.54.5"},"reference-count":27,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"unspecified","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Clinical Research Initiation-Fund"},{"name":"CREATION-Fund"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,4,1]]},"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Heart failure occasionally develops after transcatheter aortic valve implantation (TAVI) for severe aortic stenosis (AS), despite procedural success. Most cases present with mildly reduced or preserved left ventricular ejection fraction (LVEF), underscoring the role of diastolic dysfunction. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown benefits across the heart failure spectrum, independent of LVEF. The purpose of this randomised controlled trial is to determine whether adding a SGLT2 inhibitor to conventional medications improves LV diastolic function in patients with preserved LVEF after TAVI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This study is a prospective, single-centre, open-label, randomised, parallel-group, two-arm trial enrolling patients with mildly reduced or preserved LVEF (\u226540%) undergoing TAVI for severe AS. Participants will be randomised in a 1:1 ratio to receive either conventional medications plus empagliflozin or conventional medications alone. In the empagliflozin group, participants will receive conventional medical therapy plus empagliflozin 10\u2009mg orally once daily, initiated 4\u2009weeks after TAVI. Empagliflozin treatment will continue throughout the study period. Participants in the control group will receive conventional medications without empagliflozin. The primary endpoint is the change in E\/e\u2019, assessed by echocardiography from treatment initiation at 4 weeks post TAVI (day 1) to day 168 (week 24). Each group will include 50 patients, totalling 100 patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Ethical approval for this study has been obtained from the Chiba University Hospital Certified Clinical Research Review Board (CRB0111-25).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>jRCT1031250190.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-114537","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T16:00:44Z","timestamp":1777910444000},"page":"e114537","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of the efficacy of empagliflozin in patients with preserved left ventricular ejection fraction undergoing transcatheter aortic valve implantation for aortic stenosis: protocol for a randomised, open-label, controlled study"],"prefix":"10.1136","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8931-6353","authenticated-orcid":false,"given":"Shogo","family":"Okita","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2888-6160","authenticated-orcid":false,"given":"Hideki","family":"Kitahara","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayumi","family":"Shoji","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Chiba University Hospital, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3664-1158","authenticated-orcid":false,"given":"Takeshi","family":"Sugawara","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Chiba University Hospital, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ko","family":"Miyakoda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Yaginuma","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Chiba University Graduate School of Medicine, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyoshi","family":"Kanda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Chiba University Graduate School of Medicine, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makiko","family":"Kinoshita","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruka","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Suzuki-Eguchi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Takaoka","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Matsuura","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Chiba University Graduate School of Medicine, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5835-8932","authenticated-orcid":false,"given":"Yoshihito","family":"Ozawa","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Chiba University Hospital, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Hanaoka","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Chiba University Hospital, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goro","family":"Matsumiya","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Chiba University Graduate School of Medicine, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"2026062608311934000_16.5.e114537.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1814052"},{"key":"2026062608311934000_16.5.e114537.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816885"},{"key":"2026062608311934000_16.5.e114537.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400685"},{"key":"2026062608311934000_16.5.e114537.4","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1002\/ehf2.14435","article-title":"Determinants and Treatments of Heart Failure After Transcatheter Aortic Valve Implantation: Moving up a Notch","volume":"10","author":"Matsushita","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2026062608311934000_16.5.e114537.5","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.120.008959","article-title":"Determinants and Impact of Heart Failure Readmission Following Transcatheter Aortic Valve Replacement","volume":"13","author":"Auffret","year":"2020","journal-title":"Circ Cardiovasc Interv"},{"key":"2026062608311934000_16.5.e114537.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2017.09.010"},{"key":"2026062608311934000_16.5.e114537.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.04.053"},{"key":"2026062608311934000_16.5.e114537.8","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.007229","article-title":"Relative Survival After Transcatheter Aortic Valve Implantation: How Do Patients Undergoing Transcatheter Aortic Valve Implantation Fare Relative to the General Population?","volume":"6","author":"Martin","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2026062608311934000_16.5.e114537.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303"},{"key":"2026062608311934000_16.5.e114537.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190"},{"key":"2026062608311934000_16.5.e114537.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107038"},{"key":"2026062608311934000_16.5.e114537.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206286"},{"key":"2026062608311934000_16.5.e114537.13","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa2500366","article-title":"Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation","volume":"392","author":"Raposeiras-Roubin","year":"2025","journal-title":"N Engl J Med"},{"key":"2026062608311934000_16.5.e114537.14","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1253\/circj.CJ-20-0135","article-title":"JCS\/JSCS\/JATS\/JSVS 2020 Guidelines on the Management of Valvular Heart Disease","volume":"84","author":"Izumi","year":"2020","journal-title":"Circ J"},{"key":"2026062608311934000_16.5.e114537.15","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000923"},{"key":"2026062608311934000_16.5.e114537.16","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.jacasi.2022.08.007","article-title":"Outcome of Nonagenarians Undergoing Transfemoral Transcatheter Aortic Valve Replacement: A Nationwide Registry Analysis From Japan","volume":"2","author":"Higuchi","year":"2022","journal-title":"JACC Asia"},{"key":"2026062608311934000_16.5.e114537.17","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-019-06892-y"},{"key":"2026062608311934000_16.5.e114537.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.echo.2014.10.003"},{"key":"2026062608311934000_16.5.e114537.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.echo.2016.01.011"},{"key":"2026062608311934000_16.5.e114537.20","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC Basic Transl Sci"},{"key":"2026062608311934000_16.5.e114537.21","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-024-02294-z","article-title":"Dapagliflozin reduces systemic inflammation in patients with type 2 diabetes without known heart failure","volume":"23","author":"Wang","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"2026062608311934000_16.5.e114537.22","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-025-02767-9","article-title":"The effects of SGLT2i on cardiac metabolism in patients with HFpEF: Fact or fiction?","volume":"24","author":"Cinti","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"2026062608311934000_16.5.e114537.23","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.15.1788"},{"key":"2026062608311934000_16.5.e114537.24","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10557-024-07576-y","article-title":"Rationale and Design of Prospective, Multicenter, Double-Arm Clinical Trial to Investigate the Efficacy of Tofogliflozin on Left Ventricular Diastolic Dysfunction in Patients with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes Mellitus (TOP-HFPEF Trial)","volume":"39","author":"Ito","year":"2025","journal-title":"Cardiovasc Drugs Ther"},{"key":"2026062608311934000_16.5.e114537.25","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s00392-023-02164-w","article-title":"Effects of empagliflozin on left ventricular diastolic function in addition to usual care in individuals with type 2 diabetes mellitus-results from the randomized, double-blind, placebo-controlled EmDia trial","volume":"112","author":"Prochaska","year":"2023","journal-title":"Clin Res Cardiol"},{"key":"2026062608311934000_16.5.e114537.26","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-018-1344-x"},{"key":"2026062608311934000_16.5.e114537.27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-02733-w"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-114537","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T15:39:39Z","timestamp":1782488379000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-114537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":27,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,4]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1136\/bmjopen-2025-114537"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-114537","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]}}}